Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2013 (2013), Article ID 329862, 10 pages
http://dx.doi.org/10.1155/2013/329862
Research Article

Interaction Effects of the Leu162Val PPARα and Pro12Ala PPARγ2 Gene Variants with Renal Function in Metabolic Syndrome Population

1Research Unit 05/UR/09-12: Genetic and Biological Factors of Atherosclerosis, Medicine Faculty, University of Monastir, Street Fatouma Bourguiba, 5000 Monastir, Tunisia
2Department of Cardiology of the Fattouma Bourguiba University Hospital of Monastir, Tunisia
3Laboratory of Biochemistry and Toxicology of the Fattouma Bourguiba University Hospital of Monastir, Tunisia

Received 18 November 2012; Revised 4 February 2013; Accepted 8 March 2013

Academic Editor: Stéphane Mandard

Copyright © 2013 Sarraj Mohamed Youssef et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Timar, F. Sestier, and E. Levy, “Metabolic syndrome X: a review,” Canadian Journal of Cardiology, vol. 16, no. 6, pp. 779–789, 2000. View at Google Scholar · View at Scopus
  2. A. D. Liese, E. J. Mayer-Davis, H. A. Tyroler et al., “Familial components of the multiple metabolic syndrome: the ARIC study,” Diabetologia, vol. 40, no. 8, pp. 963–970, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Zatz, B. R. Dunn, T. W. Meyer, S. Anderson, H. G. Rennke, and B. M. Brenner, “Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension,” Journal of Clinical Investigation, vol. 77, no. 6, pp. 1925–1930, 1986. View at Google Scholar · View at Scopus
  4. M. E. Cooper, “Pathogenesis, prevention, and treatment of diabetic nephropathy,” The Lancet, vol. 352, no. 9123, pp. 213–219, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. P. K. Whelton, T. V. Perneger, J. He, and M. J. Klag, “The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence,” Journal of Human Hypertension, vol. 10, no. 10, pp. 683–689, 1996. View at Google Scholar · View at Scopus
  6. J. Chen, P. Muntner, L. L. Hamm et al., “The metabolic syndrome and chronic kidney disease in U.S. adults,” Annals of Internal Medicine, vol. 140, no. 3, pp. 167–174, 2004. View at Google Scholar · View at Scopus
  7. L. Palaniappan, M. Carnethon, and S. P. Fortmann, “Association between microalbuminuria and the metabolic syndrome: NHANES III,” American Journal of Hypertension, vol. 16, no. 11, pp. 952–958, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Zhang, L. Zuo, F. Wang et al., “Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older,” Mayo Clinic Proceedings, vol. 82, no. 7, pp. 822–827, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Fajas, M. B. Debril, and J. Auwerx, “Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis,” Journal of Molecular Endocrinology, vol. 27, no. 1, pp. 1–9, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Mukherjee, L. Jow, D. Noonan, and D. P. McDonnell, “Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators,” Journal of Steroid Biochemistry and Molecular Biology, vol. 51, no. 3-4, pp. 157–166, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology—Renal Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Google Scholar · View at Scopus
  14. X. Z. Ruan, J. F. Moorhead, R. Fernando, D. C. Wheeler, S. H. Powis, and Z. Varghese, “PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway,” Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 593–600, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Guan, Y. Zhang, A. Schneider, L. Davis, R. M. Breyer, and M. D. Breyer, “Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature,” American Journal of Physiology—Renal Physiology, vol. 281, no. 6, pp. F1036–F1046, 2001. View at Google Scholar · View at Scopus
  16. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse of HOMA modeling,” Diabetes Care, vol. 27, no. 6, pp. 1487–1495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Google Scholar · View at Scopus
  19. B. H. Chung, S. W. Lim, K. O. Ahn et al., “Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases,” Nephrology, vol. 10, no. 2, pp. S40–S43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Cuzzocrea, “Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury,” Vascular Pharmacology, vol. 41, no. 6, pp. 187–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Portilla, G. Dai, J. M. Peters, F. J. Gonzalez, M. D. Crew, and A. D. Proia, “Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure,” American Journal of Physiology—Renal Physiology, vol. 278, no. 4, pp. F667–F675, 2000. View at Google Scholar · View at Scopus
  22. S. Li, R. Bhatt, J. Megyesi, N. Gokden, S. V. Shah, and D. Portilla, “PPAR-α ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G,” American Journal of Physiology—Renal Physiology, vol. 287, no. 5, pp. F990–F998, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Sapone, J. M. Peters, S. Sakai et al., “The human peroxisome proliferator-activated receptor α gene: identification and functional characterization of two natural allelic variants,” Pharmacogenetics, vol. 10, no. 4, pp. 321–333, 2000. View at Google Scholar · View at Scopus
  25. M. Stumvoll, N. Stefan, A. Fritsche et al., “Interaction effect between common polymorphisms in PPARγ2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity,” Journal of Molecular Medicine, vol. 80, no. 1, pp. 33–38, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Koch, K. Rett, E. Maerker et al., “The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects,” Diabetologia, vol. 42, no. 6, pp. 758–762, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Stefan, A. Fritsche, H. Häring, and M. Stumvoll, “Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene,” Diabetes, vol. 50, no. 5, pp. 1143–1148, 2001. View at Google Scholar · View at Scopus
  28. M. Kurella, J. C. Lo, and G. M. Chertow, “Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2134–2140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Chen, D. Gu, C. S. Chen et al., “Association between the metabolic syndrome and chronic kidney disease in Chinese adults,” Nephrology Dialysis Transplantation, vol. 22, no. 4, pp. 1100–1106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Raimundo and J. A. Lopes, “Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad,” Cardiology Research and Practice, vol. 2011, Article ID 747861, 2011. View at Google Scholar
  31. T. S. Perlstein, M. Gerhard-Herman, N. K. Hollenberg, G. H. Williams, and A. Thomas, “Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 944–951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Balkau and M. A. Charles, “Comment on the provisional report from the WHO consultation,” Diabetic Medicine, vol. 16, no. 5, pp. 442–443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Khamaisi, A. Flyvbjerg, Z. Haramati, G. Raz, I. D. Wexler, and I. Raz, “Effect of mild hypoinsulinemia on renal hypertrophy: growth hormone/insulin-like growth factor 1 system in mild streptozotocin diabetes,” International Journal of Experimental Diabetes Research, vol. 3, no. 4, pp. 257–264, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Wang, M. DeNichilo, C. Brubaker, and R. Hirschberg, “Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy,” Kidney International, vol. 60, no. 1, pp. 96–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Lupia, S. J. Elliot, O. Lenz et al., “IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy,” Diabetes, vol. 48, no. 8, pp. 1638–1644, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Sjöholm and T. Nyström, “Endothelial inflammation in insulin resistance,” The Lancet, vol. 365, no. 9459, pp. 610–612, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. R. Sowers, “Metabolic risk factors and renal disease,” Kidney International, vol. 71, no. 8, pp. 719–720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Kambham, G. S. Markowitz, A. M. Valeri, J. Lin, and V. D. D'Agati, “Obesity-related glomerulopathy: an emerging epidemic,” Kidney International, vol. 59, no. 4, pp. 1498–1509, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Bhowmik and S. C. Tiwari, “Metabolic syndrome and chronic kidney disease.,” Indian Journal of Nephrology, vol. 18, no. 1, pp. 1–4, 2008. View at Publisher · View at Google Scholar
  40. X. Hou, Y. H. Shen, C. Li et al., “PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity,” Biochemical and Biophysical Research Communications, vol. 394, no. 3, pp. 653–659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas, “PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2399–2405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Bossé, S. J. Weisnage, C. Bouchard, J. P. Després, L. Louis Pérusse, and M. C. Vohl, “Combined effects of PPARγ2 P12A and PPARαL162V polymorphisms on glucose and insulin homeostasis: the québec family study,” Journal of Human Genetics, vol. 48, pp. 614–621, 2003. View at Publisher · View at Google Scholar
  43. A. Jorsal, L. Tarnow, M. Lajer et al., “The PPARγ2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy,” Molecular Genetics and Metabolism, vol. 94, no. 3, pp. 347–351, 2008. View at Publisher · View at Google Scholar · View at Scopus